• Pharmgen Science unveiled an Oct. 22, 2026, value-enhancement plan targeting FY2030 revenue of KRW 283.6 billion.
• Targets include an 8.6% return on equity and a price-to-book ratio of 1.0 times.
• Planned shareholder returns total 20–30%, through cash dividends and/or share buybacks and cancellations.
• The strategy focuses on improving cost competitiveness, expanding high-margin products and entering new markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmgen Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022800531), on October 22, 2026, and is solely responsible for the information contained therein.